Aridis Pharmaceuticals

Aridis Pharmaceuticals is a US-based biotech focused on developing first-in-class anti-infectives, primarily monoclonal antibodies, for serious respiratory infections. The company's core technology identifies potent human mAbs from convalescent patients, creating therapies with mechanisms distinct from traditional antibiotics. Its most advanced assets are AR-301 (Phase 3) for ventilator-associated pneumonia and AR-501 (Phase 2a) for cystic fibrosis, positioning it in the high-need antimicrobial resistance (AMR) space. The company is publicly traded but currently limited to trading on the OTC Expert Market.

MabIgX® platform for discovering rare, potent, fully human monoclonal antibodies from the B-cells of convalescent patients.

Aridis competes in the novel anti-infective space with other companies developing monoclonal antibodies against bacterial toxins (e.g., Arsanis/ XBiotech, MedImmune) and next-generation antibiotics. For AR-501, it faces competition from other CF therapies and inhaled antibiotics. The landscape is fragmented but features well-funded players.